Sato Nana, Saiki Chikako, Tamiya Junko, Imai Toshio, Sunada Katsuhisa
Department of Dental Anesthesiology, School of Life Dentistry at Tokyo, The Nippon Dental University, Tokyo, Japan.
Department of Physiology, School of Life Dentistry at Tokyo, The Nippon Dental University, Tokyo, Japan.
Paediatr Anaesth. 2017 May;27(5):506-515. doi: 10.1111/pan.13107. Epub 2017 Feb 8.
Dexmedetomidine is an alpha-2 (α ) adrenoceptor and imidazoline 1 (I ) receptor agonist that provides sedation without loss of respiratory drive.
The aim of this study was to elucidate the involvement of α -adrenoceptor and I receptor in the cardiorespiratory changes induced by dexmedetomidine in spontaneously breathing newborn rats.
An abdominal catheter to administer drugs and three subcutaneous electrodes to record electrocardiographic data were inserted into 2- to 5-day-old Wistar rats under isoflurane anesthesia. In individual chambers, each rat was intraperitoneally administered dexmedetomidine (50 μg·kg ) followed 5 min later by normal saline or 1, 5, or 10 mg·kg atipamezole (selective α -adrenoceptor antagonist) or efaroxan (α -adrenoceptor/I receptor antagonist). Cardiorespiratory indices were recorded before and after drug administration.
The administration of dexmedetomidine alone resulted in significant changes to most of the cardiorespiratory indices examined. The addition of 5 or 10 mg·kg atipamezole or 1 mg·kg efaroxan completely ameliorated the dexmedetomidine-associated reduction in heart rate (HR). The addition of 1 mg·kg atipamezole or 1 or 5 mg·kg efaroxan completely ameliorated the dexmedetomidine-associated reduction in respiratory frequency. Mean inspiratory flow (V /T ; V is tidal volume and T is inspiratory time), which is an index of respiratory drive, was not significantly affected by the administration of dexmedetomidine alone (P = 0.273) or dexmedetomidine + atipamezole (P = 0.605, 0.153, 0.138 for 1, 5, 10 mg·kg atipamezole, respectively); however, it was significantly decreased after the administration of dexmedetomidine + efaroxan (P = 0.029, <0.001, <0.001 for 1, 5, 10 mg·kg efaroxan, respectively).
Our results suggest that in newborn rats undergoing dexmedetomidine sedation, the α -adrenoceptor, but not I receptor, is involved in the regulation of HR and respiratory frequency, and that activation of the I receptor plays a major role in the maintenance of respiratory drive.
右美托咪定是一种α2(α)肾上腺素能受体和咪唑啉1(I)受体激动剂,可提供镇静作用而不影响呼吸驱动。
本研究旨在阐明α肾上腺素能受体和I受体在右美托咪定诱导的自主呼吸新生大鼠心肺变化中的作用。
在异氟烷麻醉下,将一根用于给药的腹腔导管和三根用于记录心电图数据的皮下电极插入2至5日龄的Wistar大鼠体内。在单独的实验箱中,每只大鼠腹腔注射右美托咪定(50μg·kg),5分钟后再腹腔注射生理盐水或1、5或10mg·kg的阿替美唑(选择性α肾上腺素能受体拮抗剂)或依酚氯铵(α肾上腺素能受体/I受体拮抗剂)。在给药前后记录心肺指标。
单独注射右美托咪定导致所检测的大多数心肺指标发生显著变化。添加5或10mg·kg的阿替美唑或1mg·kg的依酚氯铵可完全改善右美托咪定引起的心率(HR)降低。添加1mg·kg的阿替美唑或1或5mg·kg的依酚氯铵可完全改善右美托咪定引起的呼吸频率降低。平均吸气流量(V/T;V为潮气量,T为吸气时间),作为呼吸驱动的指标,单独注射右美托咪定(P = 0.273)或右美托咪定+阿替美唑(分别为1、5、10mg·kg阿替美唑时,P = 0.605、0.153、0.138)对其无显著影响;然而,注射右美托咪定+依酚氯铵后其显著降低(分别为1、5、10mg·kg依酚氯铵时,P = 0.029、<0.001、<0.001)。
我们的结果表明,在接受右美托咪定镇静的新生大鼠中,α肾上腺素能受体而非I受体参与心率和呼吸频率的调节,且I受体的激活在维持呼吸驱动中起主要作用。